The release of the snapshot containing the respective simulations can be found here:
https://github.com/Open-Systems-Pharmacology/Fluvoxamine-Alprazolam-DDI/releases/tag/v1.1

The fluvoxamine-alprazolam interaction was evaluated using one clinical DDI study quantifying the interaction following the first dose and in steady-state ([Fleishaker 1994](#4-references)).



| DataID | Enzyme | Perpetrator / victim     | Study design                                                 | Clinical study                   |
| ------ | ------ | ------------------------ | ------------------------------------------------------------ | -------------------------------- |
| 1104   | CYP3A4 | Fluvoxamine / alprazolam | Fluvoxamine: 50 mg fluvoxamine maleate QD for 3 days, followed by 100 mg fluvoxamine maleate QD for 7 days<br />Alprazolam: 1 mg po four times daily on Day 7 starting together with the 7<sup>th</sup> fluvoxamine dose | [Fleishaker 1994](#4-references) |
| 1113   | CYP3A4 | Fluvoxamine / alprazolam | Fluvoxamine: 50 mg fluvoxamine maleate QD for 3 days, followed by 100 mg fluvoxamine maleate QD for 7 days<br />Alprazolam: 1 mg po four times daily on Days 7 - 10 starting together with the 7<sup>th</sup> fluvoxamine dose | [Fleishaker 1994](#4-references) |


